Zymergen has purchased Lodo Therapeutics, which is advancing Rockefeller research, for an undisclosed sum five years after the company raised its only funding round.

Lodo Therapeutics, a US-based drug developer based on research at Rockefeller University, has been acquired by biomanufacturer Zymergen for an undisclosed amount. Lodo Therapeutics is working on therapeutics that address targets previously deemed undruggable by tapping into molecules encoded in environmental microbial DNA. The company was co-founded by Sean Brady, head of Rockefeller University’s Laboratory…

The rest of this content is only accessible to University Venturing: News, Data, and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.